Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Wonder drugs’ like Ozempic, hailed by celebrities and some medics as a cure for an ever-mounting list of conditions, most notably obesity and diabetes, have started to appear in darker headlines ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Likewise, the injected Zepbound® resulted in 22 gastrointestinal ("GI")-related adverse events, whereas the oral DehydraTECH-tirzepatide ... most commonly cited side effects of today's leading ...

The Study was designed to measure tolerability and side effects, blood levels of tirzepatide, and blood glucose and insulin levels. The DehydraTECH-tirzepatide composition was formulated at a ...

PEOPLE TAKING GLP-1S have a reduced risk of heart attacks, strokes, and death from cardiovascular disease, according to a ...

Weight loss drugs like Ozempic and wegovy have become global sensation. In the recent years, companies like Novo Nordisk and Eli Lilly have GLP-1 agonists and dual GLP-1/GIP receptor agonists that ...

The DehydraTECH-tirzepatide test articles were compound formulated using Zepbound®, strictly for research purposes, and dosed orally to the subjects under fasted conditions. The Study was ...